This German Biotech Just Raised Millions to Target a Silent Killer

Jan de Vries · 2026-08-28

A fresh biotech player from Heidelberg, Germany, is stepping into the ring with a new weapon against some of the world's most persistent cardiovascular diseases. Revier Therapeutics has officially launched, announcing a seed financing round of approximately $6.4 million to fuel its ambitious mission. Here's the thing. Despite all the advances in medicine, millions of people are still stuck with limited options for serious heart conditions. The company's founders saw this gap and decided to build a new approach from the ground up. ### The Funding and the Backing The $6.4 million seed round is a strong vote of confidence. It was led by the KHAN Technology Transfer Fund II. They weren't alone—High-Tech Gründerfonds (HTGF), VORNvc, and private investors through Revier Invest Heidelberg all joined in. It's a coalition that believes in the science. This isn't just about money. It's about regional support and deep expertise coming together to back a novel idea. Business developer Daniel Stern, founder of Revier Invest Heidelberg, helped pull this coalition of stakeholders together. ### The Problem They're Solving Let's talk about the 'why.' Prof. Eva van Rooij, PhD, the company's co-founder and CEO, puts it plainly. "Millions of patients with HFpEF and ASCVD still face limited targeted treatment options," she says. HFpEF is heart failure with preserved ejection fraction, and ASCVD is atherosclerotic cardiovascular disease. In simpler terms? These are complex, life-altering conditions where current treatments often manage symptoms but don't modify the underlying disease. The next generation of medicine needs to go deeper. ### A New Class of Medicine So, what's their big idea? Revier is pioneering the first therapeutic approach to selectively target a specific family of enzymes called class IIa histone deacetylases (HDACs) for cardiometabolic diseases. Think of HDACs as regulators inside our cells; when they malfunction, they can drive disease. Previous HDAC inhibitors were like blunt instruments—they hit too many targets and caused serious side effects. Revier's orally available small molecules are designed to be precision tools. Prof. Johannes Backs, MD, the scientific founder, explains the difference. "Revier’s first-in-class small molecules selectively target class IIa HDACs. They inhibit the disease-driving activity while preserving essential healthy functions." The goal is a therapy that's both powerful and safe. ### Why This Matters for the Ecosystem Michael Hamacher, PhD, of KHAN Technology Transfer Fund II, highlighted the strategic bet. "Revier’s differentiated strategy has the potential to unlock the therapeutic promise of HDAC biology while overcoming past limitations," he said. He points to the exceptional leadership and deep science as key reasons for their support. The potential impact is huge. It's not just about a new drug; it's about potentially reshaping the standard of care for chronic conditions that affect countless lives. ### What's Next for the Capital? The freshly raised capital has a clear job. It will push forward the company's preclinical pipeline, focusing on two main programs: - Their lead program targeting HFpEF. - A second program for ASCVD. Beyond the lab work, the funds will help build out the team—adding operational, scientific, and clinical muscle to turn this promising science into real-world treatments. It's a classic startup story: big problem, novel science, smart funding, and a long road ahead. But for patients waiting on better options, it's a path worth watching.